Chiara Bazzini
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Chiara Bazzini has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Carlo Ferrarese
Department of Medicine and Surgery and Milan Center for Neuroscience (NeuroMI) (F.A.P., S.D., C.F., S.B.), University of Milano-Bicocca, Monza, Italy
2 shared publications - Chiara Paola Zoia
Department of Medicine and Surgery, University of Milano-Bicocca, Italy (F.A.P., M.F., G.M., A.G., C.S., C.B., C.P.Z., J.M., C.F., S.B.).
2 shared publications - Elisa Conti
School of Medicine and Surgery, University of Milano-Bicocca, Milano, Italy
2 shared publications - Federica Piancone
IRCCS Fondazione Don Carlo Gnocchi, 20148 Milan, Italy
2 shared publications - Francesca La Rosa
IRCCS Fondazione Don Carlo Gnocchi, 20148 Milan, Italy
2 shared publications - Ivana Marventano
IRCCS Fondazione Don Carlo Gnocchi, 20148 Milan, Italy
2 shared publications
Latest Publications
- 17 September 2026
- Published by SAGE Publications in Journal of Cerebral Blood Flow & Metabolism
Longitudinal circulating miRNA profiling identifies pharmacodynamic biomarkers of remote ischemic conditioning in acute ischemic stroke: A translational sub-study of the randomized TRICS-9 trial
Background: Remote ischemic conditioning (RIC) is a promising neuroprotective strategy for ischemic stroke, but reliable pharmacodynamic biomarkers confirming its biological activity are lacking. Methods: In this translational sub-study of the multicenter randomized phase II TRICS-9 trial, we profiled five circulating microRNAs (miR-181b, miR-150, miR-143, miR-223, and let-7a) in 42 acute stroke patients assigned to RIC or standard medical therapy at 24 h and 72 h post-randomization. Results: At 24 h, miR-143, miR-150, and let-7a were significantly lower in RIC patients, with miR-143 and miR-150 showing strong pharmacodynamic biomarker performance in receiver operating characteristic analysis. At 72 h, miR-181b was significantly elevated in RIC patients, while let-7a and miR-223 remained suppressed. Longitudinal paired analysis revealed significant within-patient temporal increases in miR-181b, miR-150, and miR-143 from 24 to 72 h in RIC patients consistent with a biphasic molecular response to conditioning. Conclusions: These findings identify miR-143, miR-150, let-7a, and miR-181b as candidate pharmacodynamic biomarkers of RIC biological activity. Importantly, none of the candidate miRNAs demonstrated significant correlation with stroke severity, discharge NIHSS, or 90-day functional outcome, consistent with their role as pharmacodynamic rather than prognostic markers. These results provide mechanistic support for translational convergence between preclinical and clinical RIC neuroprotection research and highlight the need for external validation in larger outcome-linked cohorts.
- 17 September 2026
- Published by SAGE Publications in Journal of Cerebral Blood Flow & Metabolism
Longitudinal circulating miRNA profiling identifies pharmacodynamic biomarkers of remote ischemic conditioning in acute ischemic stroke: A translational sub-study of the randomized TRICS-9 trial
Background: Remote ischemic conditioning (RIC) is a promising neuroprotective strategy for ischemic stroke, but reliable pharmacodynamic biomarkers confirming its biological activity are lacking. Methods: In this translational sub-study of the multicenter randomized phase II TRICS-9 trial, we profiled five circulating microRNAs (miR-181b, miR-150, miR-143, miR-223, and let-7a) in 42 acute stroke patients assigned to RIC or standard medical therapy at 24 h and 72 h post-randomization. Results: At 24 h, miR-143, miR-150, and let-7a were significantly lower in RIC patients, with miR-143 and miR-150 showing strong pharmacodynamic biomarker performance in receiver operating characteristic analysis. At 72 h, miR-181b was significantly elevated in RIC patients, while let-7a and miR-223 remained suppressed. Longitudinal paired analysis revealed significant within-patient temporal increases in miR-181b, miR-150, and miR-143 from 24 to 72 h in RIC patients consistent with a biphasic molecular response to conditioning. Conclusions: These findings identify miR-143, miR-150, let-7a, and miR-181b as candidate pharmacodynamic biomarkers of RIC biological activity. Importantly, none of the candidate miRNAs demonstrated significant correlation with stroke severity, discharge NIHSS, or 90-day functional outcome, consistent with their role as pharmacodynamic rather than prognostic markers. These results provide mechanistic support for translational convergence between preclinical and clinical RIC neuroprotection research and highlight the need for external validation in larger outcome-linked cohorts.
- Open Access
- 13 December 2023
- Published by MDPI AG in Pharmaceuticals
- Vol. 16 (12) , 1725
Glibenclamide-Loaded Engineered Nanovectors (GNVs) Modulate Autophagy and NLRP3-Inflammasome Activation
Activation of the NLRP3 inflammasome in response to either exogenous (PAMPs) or endogenous (DAMPs) stimuli results in the production of IL-18, caspase-1 and IL-1β. These cytokines have a beneficial role in promoting inflammation, but an excessive activation of the inflammasome and the consequent constitutive inflammatory status plays a role in human pathologies, including Alzheimer’s disease (AD). Autophagic removal of NLRP3 inflammasome activators can reduce inflammasome activation and inflammation. Likewise, inflammasome signaling pathways regulate autophagy, allowing the development of inflammatory responses but preventing excessive and detrimental inflammation. Nanotechnology led to the development of liposome engineered nanovectors (NVs) that can load and carry drugs. We verified in an in vitro model of AD-associated inflammation the ability of Glibenclamide-loaded NVs (GNVs) to modulate the balance between inflammasome activation and autophagy. Human THP1dM cells were LPS-primed and oligomeric Aß-stimulated in the presence/absence of GNVs. IL-1β, IL-18 and activated caspase-1 production was evaluated by the Automated Immunoassay System (ELLA); ASC speck formation (a marker of NLRP3 activation) was analyzed by FlowSight Imaging flow-cytometer (AMNIS); the expression of autophagy targets was investigated by RT-PCR and Western blot (WB); and the modulation of autophagy-related up-stream signaling pathways and Tau phosphorylation were WB-quantified. Results showed that GNVs reduce activation of the NLRP3 inflammasome and prevent the Aß-induced phosphorylation of ERK, AKT, and p70S6 kinases, potentiating autophagic flux and counteracting Tau phosphorylation. These preliminary results support the investigation of GNVs as a possible novel strategy in disease and rehabilitation to reduce inflammasome-associated inflammation.
- 13 December 2023
- Published by MDPI AG in Pharmaceuticals
- Vol. 16 (12) , 1725
Open AccessGlibenclamide-Loaded Engineered Nanovectors (GNVs) Modulate Autophagy and NLRP3-Inflammasome Activation
Activation of the NLRP3 inflammasome in response to either exogenous (PAMPs) or endogenous (DAMPs) stimuli results in the production of IL-18, caspase-1 and IL-1β. These cytokines have a beneficial role in promoting inflammation, but an excessive activation of the inflammasome and the consequent constitutive inflammatory status plays a role in human pathologies, including Alzheimer’s disease (AD). Autophagic removal of NLRP3 inflammasome activators can reduce inflammasome activation and inflammation. Likewise, inflammasome signaling pathways regulate autophagy, allowing the development of inflammatory responses but preventing excessive and detrimental inflammation. Nanotechnology led to the development of liposome engineered nanovectors (NVs) that can load and carry drugs. We verified in an in vitro model of AD-associated inflammation the ability of Glibenclamide-loaded NVs (GNVs) to modulate the balance between inflammasome activation and autophagy. Human THP1dM cells were LPS-primed and oligomeric Aß-stimulated in the presence/absence of GNVs. IL-1β, IL-18 and activated caspase-1 production was evaluated by the Automated Immunoassay System (ELLA); ASC speck formation (a marker of NLRP3 activation) was analyzed by FlowSight Imaging flow-cytometer (AMNIS); the expression of autophagy targets was investigated by RT-PCR and Western blot (WB); and the modulation of autophagy-related up-stream signaling pathways and Tau phosphorylation were WB-quantified. Results showed that GNVs reduce activation of the NLRP3 inflammasome and prevent the Aß-induced phosphorylation of ERK, AKT, and p70S6 kinases, potentiating autophagic flux and counteracting Tau phosphorylation. These preliminary results support the investigation of GNVs as a possible novel strategy in disease and rehabilitation to reduce inflammasome-associated inflammation.
- Open Access
Modulation of MAPK- and PI3/AKT-Dependent Autophagy Signaling by Stavudine (D4T) in PBMC of Alzheimer’s Disease Patients
Background: Aβ42 deposition plays a pivotal role in AD pathogenesis by inducing the activation of microglial cells and neuroinflammation. This process is antagonized by microglia-mediated clearance of Aβ plaques. Activation of the NLRP3 inflammasome is involved in neuroinflammation and in the impairments of Aβ-plaque clearance. On the other hand, stavudine (D4T) downregulates the NLRP3 inflammasome and stimulates autophagy-mediated Aβ-clearing in a THP-1-derived macrophages. Methods: We explored the effect of D4T on Aβ autophagy in PBMC from AD patients that were primed with LPS and stimulated with Aβ oligomers in the absence/presence of D4T. We analyzed the NLRP3 activity by measuring NLRP3-ASC complex formation by AMNIS FlowSight and pro-inflammatory cytokine (IL-1β, IL-18 and Caspase-1) production by ELISA. The phosphorylation status of p38, ERK, AKT, p70, and the protein expression of CREB, LAMP2A, beclin-1, Caspase-3 and Bcl2 were analyzed by Western blot. Results: Data showed that D4T: (1) downregulates NLRP3 inflammasome activation and the production of down-stream pro-inflammatory cytokines in PBMC; (2) stimulates the phosphorylation of AKT, ERK and p70 as well as LAMP2A, beclin-1 and Bcl2 expression and reduces Caspase-3 expression, suggesting an effect of this compound on autophagy; (3) increases phospho-CREB, which is a downstream target of p-ERK and p-AKT, inducing anti-inflammatory cytokine production and resulting in a possible decrease of Aβ-mediated cytotoxicity; and (4) reduces the phosphorylation of p38, a protein involved in the production of pro-inflammatory cytokines and tau hyperphosphorylation. Conclusions: D4T reduces the activation of the NLRP3 inflammasome, and it might stimulate autophagy as well as the molecular mechanism that modulates Aβ cytotoxicity, and D4T might reduce inflammation in the cells of AD patients. It could be very interesting to check the possible beneficial effects of D4T in the clinical scenario.
Open AccessModulation of MAPK- and PI3/AKT-Dependent Autophagy Signaling by Stavudine (D4T) in PBMC of Alzheimer’s Disease Patients
Background: Aβ42 deposition plays a pivotal role in AD pathogenesis by inducing the activation of microglial cells and neuroinflammation. This process is antagonized by microglia-mediated clearance of Aβ plaques. Activation of the NLRP3 inflammasome is involved in neuroinflammation and in the impairments of Aβ-plaque clearance. On the other hand, stavudine (D4T) downregulates the NLRP3 inflammasome and stimulates autophagy-mediated Aβ-clearing in a THP-1-derived macrophages. Methods: We explored the effect of D4T on Aβ autophagy in PBMC from AD patients that were primed with LPS and stimulated with Aβ oligomers in the absence/presence of D4T. We analyzed the NLRP3 activity by measuring NLRP3-ASC complex formation by AMNIS FlowSight and pro-inflammatory cytokine (IL-1β, IL-18 and Caspase-1) production by ELISA. The phosphorylation status of p38, ERK, AKT, p70, and the protein expression of CREB, LAMP2A, beclin-1, Caspase-3 and Bcl2 were analyzed by Western blot. Results: Data showed that D4T: (1) downregulates NLRP3 inflammasome activation and the production of down-stream pro-inflammatory cytokines in PBMC; (2) stimulates the phosphorylation of AKT, ERK and p70 as well as LAMP2A, beclin-1 and Bcl2 expression and reduces Caspase-3 expression, suggesting an effect of this compound on autophagy; (3) increases phospho-CREB, which is a downstream target of p-ERK and p-AKT, inducing anti-inflammatory cytokine production and resulting in a possible decrease of Aβ-mediated cytotoxicity; and (4) reduces the phosphorylation of p38, a protein involved in the production of pro-inflammatory cytokines and tau hyperphosphorylation. Conclusions: D4T reduces the activation of the NLRP3 inflammasome, and it might stimulate autophagy as well as the molecular mechanism that modulates Aβ cytotoxicity, and D4T might reduce inflammation in the cells of AD patients. It could be very interesting to check the possible beneficial effects of D4T in the clinical scenario.
- Open Access
- 1 October 2021
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 141 (10) , S181
186 TH9 cells depend on cystine uptake and PPAR-γ signaling to prevent unchecked lipid ROS and cell death
- 1 October 2021
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 141 (10) , S181
Open Access186 TH9 cells depend on cystine uptake and PPAR-γ signaling to prevent unchecked lipid ROS and cell death